Literature DB >> 1422923

Inhibition of sulfur mustard-increased protease activity by niacinamide, N-acetyl-L-cysteine or dexamethasone.

F M Cowan1, C A Broomfield, W J Smith.   

Abstract

The pathologic mechanisms underlying sulfur mustard-induced skin vesication remain undefined. Papirmeister et al. (1985) have postulated a biochemical mechanism for sulfur mustard-induced cutaneous injury involving DNA alkylation, metabolic disruption, and enhanced proteolytic activity. We have previously utilized a chromogenic peptide substrate assay to establish that human peripheral blood lymphocytes exposed to sulfur mustard exhibited enhanced proteolytic activity. In this study, compounds known to alter the biochemical events associated with sulfur mustard exposure or to reduce protease activity were tested for their ability to block the sulfur mustard-increased proteolysis. Treatment of cells with niacinamide, N-acetyl-L-cysteine, or dexamethasone resulted in a decrease of sulfur mustard-increased protease activity. Complete inhibition of sulfur mustard-increased proteolysis was achieved by using protease inhibitors (antipain, leupeptin, and 4-(2-aminoethyl)-benzenesulfonylfluoride). These data suggest that therapeutic intervention in the biochemical pathways that culminate in protease activation or direct inhibition of proteolysis might serve as an approach to the treatment of sulfur mustard-induced pathology.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1422923     DOI: 10.1007/bf00260563

Source DB:  PubMed          Journal:  Cell Biol Toxicol        ISSN: 0742-2091            Impact factor:   6.691


  6 in total

1.  Molecular basis for mustard-induced vesication.

Authors:  B Papirmeister; C L Gross; H L Meier; J P Petrali; J B Johnson
Journal:  Fundam Appl Toxicol       Date:  1985-12

2.  Chromogenic peptide substrates. Their use for the assay of factors in the fibrinolytic and the plasma kallikrein-kinin systems.

Authors:  P Friberger
Journal:  Scand J Clin Lab Invest Suppl       Date:  1982

3.  Dexamethasone-induced plasminogen activator inhibitor: characterization, purification, and preparation of monoclonal antibodies.

Authors:  A Oikarinen; M Höyhtyä; M Järvinen
Journal:  Arch Dermatol Res       Date:  1990       Impact factor: 3.017

4.  Effect of sulfur exposure on protease activity in human peripheral blood lymphocytes.

Authors:  F M Cowan; C A Broomfield; W J Smith
Journal:  Cell Biol Toxicol       Date:  1991-07       Impact factor: 6.691

5.  2,2'-Dichlorodiethyl sulfide (sulfur mustard) decreases NAD+ levels in human leukocytes.

Authors:  H L Meier; C L Gross; B Papirmeister
Journal:  Toxicol Lett       Date:  1987-11       Impact factor: 4.372

6.  Niacinamide pretreatment reduces microvesicle formation in hairless guinea pigs cutaneously exposed to sulfur mustard.

Authors:  J J Yourick; C R Clark; L W Mitcheltree
Journal:  Fundam Appl Toxicol       Date:  1991-10
  6 in total
  5 in total

Review 1.  Putative roles of inflammation in the dermatopathology of sulfur mustard.

Authors:  F M Cowan; C A Broomfield
Journal:  Cell Biol Toxicol       Date:  1993 Jul-Sep       Impact factor: 6.691

2.  Sulfur mustard-increased proteolysis following in vitro and in vivo exposures.

Authors:  F M Cowan; J J Yourick; C G Hurst; C A Broomfield; W J Smith
Journal:  Cell Biol Toxicol       Date:  1993 Jul-Sep       Impact factor: 6.691

Review 3.  Ocular toxicity of mustard gas: A concise review.

Authors:  Allison Fuchs; Elizabeth A Giuliano; Nishant R Sinha; Rajiv R Mohan
Journal:  Toxicol Lett       Date:  2021-02-15       Impact factor: 4.271

4.  Sulfur mustard-stimulated proteases and their inhibitors in a cultured normal human epidermal keratinocytes model: A potential approach for anti-vesicant drug development.

Authors:  Xiannu Jin; Radharaman Ray; Prabhati Ray
Journal:  Toxicol Rep       Date:  2016-03-15

Review 5.  N-Acetylcysteine as a treatment for sulphur mustard poisoning.

Authors:  Thomas W Sawyer
Journal:  Free Radic Biol Med       Date:  2020-09-25       Impact factor: 7.376

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.